JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
Status:
Completed
Trial end date:
2017-09-24
Target enrollment:
Participant gender:
Summary
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily
and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in
patients with biopsy-proven nonalcoholic steatohepatitis